PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Tracy Staton

Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech have multiplied in cases across the country, testing that Second Circuit decision in other regions.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS